|
|
Vaccine Detail
|
Recombinant Vaccinia DF3/MUC1 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia DF3/MUC1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007017
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MUC1
gene engineering:
- KLK3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Eder et al., 2000)
- Detailed Gene Information: Click Here.
- Preparation: A modified vaccinia virus is used as vector to deliver DNA sequences coding for the human MUC1 antigen (Rochlitz et al., 2003).
- Description: This is for Breast Cancer (NCT00071942). A vaccinia virus based vaccine expressing human tumor associated epithelial mucin (DF3 antigen; MUC1). MUC1 antigen, a membrane bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in various tumors such as breast, prostate, and ovarian cancers. This vaccine could be used in development of immunotherapeutics against cancers expressing MUC1 (Akagi et al., 1997; NCIT_C2510).
|
| Host Response |
|
|
| References |
Akagi et al., 1997: Akagi J, Hodge JW, McLaughlin JP, Gritz L, Mazzara G, Kufe D, Schlom J, Kantor JA. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. Journal of immunotherapy (Hagerstown, Md. : 1997). 1997; 20(1); 38-47. [PubMed: 9101412].
Eder et al., 2000: Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000; 6(5); 1632-1638. [PubMed: 10815880].
NCIT_C2510: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2510]
NCT00071942: [https://clinicaltrials.gov/show/NCT00071942/]
Rochlitz et al., 2003: Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. The journal of gene medicine. 2003; 5(8); 690-699. [PubMed: 12898638].
|
|
